2920-86-7 Usage
Description
Prednisolone succinate, also known as Prednisolone hemisuccinate, is a synthetic glucocorticoid derived from cortisol. It is a metabolite of Prednisolone and possesses potent anti-inflammatory and immunosuppressive properties. Prednisolone succinate is widely used in the medical field for the treatment of various inflammatory and autoimmune conditions due to its ability to modulate the immune system and reduce inflammation.
Uses
Used in Pharmaceutical Industry:
Prednisolone succinate is used as an anti-inflammatory and immunosuppressive agent for the treatment of various inflammatory and autoimmune conditions. It is particularly effective in managing conditions such as rheumatoid arthritis, lupus, asthma, and allergies. The drug works by suppressing the immune system and reducing inflammation, providing relief from symptoms and preventing further damage to the affected tissues.
Used in Treatment of Inflammatory Conditions:
Prednisolone succinate is used as a therapeutic agent for the treatment of various inflammatory conditions, including acute and chronic inflammation. It helps to reduce swelling, redness, and pain associated with inflammation, promoting faster recovery and improved quality of life for patients.
Used in Autoimmune Disease Management:
Prednisolone succinate is used as a disease-modifying agent in the management of autoimmune diseases. It helps to regulate the immune system, reducing the severity and frequency of flare-ups and preventing long-term damage to the body's tissues and organs.
Used in Respiratory Conditions:
Prednisolone succinate is used as a bronchodilator and anti-inflammatory agent in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It helps to relax the airways, reduce inflammation, and improve lung function, providing relief from symptoms and improving overall respiratory health.
Used in Ophthalmology:
Prednisolone succinate is used as an anti-inflammatory agent in ophthalmology for the treatment of eye conditions such as uveitis, iritis, and allergic conjunctivitis. It helps to reduce inflammation, redness, and discomfort, promoting faster healing and preserving vision.
Used in Dermatology:
Prednisolone succinate is used as a topical anti-inflammatory agent in dermatology for the treatment of various skin conditions, including eczema, psoriasis, and contact dermatitis. It helps to reduce inflammation, itching, and redness, promoting faster healing and improving the appearance of the skin.
Used in Gastroenterology:
Prednisolone succinate is used as an anti-inflammatory agent in gastroenterology for the treatment of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. It helps to reduce inflammation in the gastrointestinal tract, alleviating symptoms and promoting healing.
Used in Nephrology:
Prednisolone succinate is used as an immunosuppressive agent in nephrology for the treatment of kidney conditions, such as nephrotic syndrome and lupus nephritis. It helps to reduce inflammation and protect the kidneys from further damage, improving renal function and overall health.
Used in Neurology:
Prednisolone succinate is used as an anti-inflammatory agent in neurology for the treatment of conditions such as multiple sclerosis and neuromyelitis optica. It helps to reduce inflammation in the central nervous system, slowing down the progression of the disease and improving the patient's quality of life.
Used in Hematology:
Prednisolone succinate is used as an immunosuppressive agent in hematology for the treatment of conditions like idiopathic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA). It helps to regulate the immune system, increasing platelet count and reducing the destruction of red blood cells, respectively.
Used in Rheumatology:
Prednisolone succinate is used as a disease-modifying antirheumatic drug (DMARD) in rheumatology for the treatment of various rheumatic diseases, such as rheumatoid arthritis and ankylosing spondylitis. It helps to reduce inflammation, alleviate pain, and prevent joint damage, improving the patient's mobility and quality of life.
Check Digit Verification of cas no
The CAS Registry Mumber 2920-86-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,2 and 0 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2920-86:
(6*2)+(5*9)+(4*2)+(3*0)+(2*8)+(1*6)=87
87 % 10 = 7
So 2920-86-7 is a valid CAS Registry Number.
InChI:InChI=1/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16?,17?,18-,22?,23-,24-,25-/m0/s1
2920-86-7Relevant articles and documents
Prednisolone artificial antigen and preparation method and application thereof
-
Paragraph 0040; 0041; 0042; 0043; 0044, (2017/01/02)
The invention discloses a prednisolone artificial antigen and a preparation method and an application thereof. The prednisolone artificial antigen provided by the invention is an antigen obtained by coupling a prednisolone hapten represented by the formula I with a vector protein. The prednisolone artificial antigen provided by the invention has the advantages of simple synthetic method, high purity and high yield, and has significant value to preparation of a prednisolone antibody and detection of prednisolone drug residues.
Prednisolone-α-cyclodextrin-star PEG polypseudorotaxanes with controlled drug delivery properties
Bilkova, Elika,Sedlak, Milo,Dvoak, Bohuslav,Ventura, Karel,Knotek, Petr,Benes, Ludvik
experimental part, p. 5423 - 5430 (2011/01/11)
The reaction of α-amino-ω-methoxypoly(ethylene glycol) [M = 5000] or star α-amino-poly(ethylene glycol) [M = 20000] with hemiesters of prednisolone dicarboxylic acids (succinic, glutaric, adipic, phthalic acid) has been used to prepare the corresponding conjugates. The rate of esterase catalyzed hydrolysis of the conjugates is controlled by the molecular mass of poly(ethylene glycol) and the length of the linker between prednisolone and poly(ethylene glycol) (τ1/2 ～ 5-0.5 h). The enzymatic hydrolysis proceeds most rapidly at conjugates with linkers derived from adipic and phthalic acids. The synthesized conjugates form polypseudorotaxanes with α-cyclodextrin which were characterized by 2D NOESY NMR spectra, powder X-ray diffraction patterns and in one case also by STM microscopy. In the case of the polypseudorotaxane having the linker derived from adipic acid, the enzymatic release proceeds ca. five times slower in comparison with the rate of prednisolone release from the corresponding conjugate. The rate of prednisolone release from the carrier can be controlled by three factors: character of the linker between the polymeric carrier and prednisolone, the molecular mass of poly(ethylene glycol) and complex formation with α-cyclodextrin. The synthesized polypseudorotaxanes represent new promising transport systems intended for targeted release of prednisolone in transplanted liver.
Studies on the reductively triggered release of heterocyclic and steroid drugs from 5-nitrothien-2-ylmethyl prodrugs
Ferrer, Sandra,Naughton, Declan P.,Threadgill, Michael D.
, p. 3437 - 3444 (2007/10/03)
Hypoxia (inadequate concentrations of dioxygen in tissues) is present in several disease states, including cancer and rheumatoid arthritis. Prodrug systems, which after bioreduction, selectively release active drugs in these tissues may be important in therapy. The 5-nitrothien-2-ylmethyl ester of aspirin was synthesised by treatment of 5-nitrothiophene-2-methanol with 2-acetoxybenzoyl chloride, whereas that of prednisolone hemisuccinate was prepared by reaction of prednisolone with 5-nitrothien-2-ylmethyl pentafluorophenyl butanedioate. In chemical model systems, both of these ester-linked potential prodrugs suffered hydrolysis, rather than reductively triggered release of the corresponding drug. 1-(5-Nitrothien-2-ylmethoxy)isoquinolines released the corresponding isoquinolin-1-ones (potent inhibitors of poly(ADP-ribose)polymerase) rapidly upon reduction of the nitro group with sodium borohydride/palladium, showing that these may be useful as reductively triggered prodrugs. In approaches to N-linked potential prodrugs, isoquinolin-1-one and nifedipine (a 1,4-dihydropyridine Ca2+ channel antagonist) were alkylated at nitrogen by 2-chloromethylthiophene but the corresponding 5-nitrothien-2-ylmethyl derivatives were synthetically inaccessible.
